1. Scrip
  2. >>Business

‘New GSK’ Still Has Some Convincing To Do

Vaccine And Speciality Medicines The Focus

 
• By Andrew McConaghie

Once the consumer health division is spun out in mid-2022, a leaner ‘new GSK’ must set about delivering on its promising pipeline – and proving its skeptics wrong.

GSK syringes
The 'New GSK' aims to deliver growth from its vaccines and speciality medicines pipeline, plus a steady but flat income from established general medicines. • Source: Alamy

GlaxoSmithKline has unveiled its strategy for growth over the next 10 years, arguing it can achieve a compound annual growth rate of more than 5% in revenues and 10% in profits, based on a new wave of innovative products.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

In Brief: Merck To Invest $1bn In New US Biologics Production

 
• By Sushmita Panda

Merck is investing $ 1bn in a Delaware facility to produce Keytruda and expand biologics manufacturing amid US tariff concerns.

Can European Biotech Survive And Thrive In Era Of Instability?

 
• By Andrew McConaghie

Europe's biopharma sector could suffer if the Trump administration incentivizes US investment but VC leaders believe the region can still thrive and potentially capitalize on instability elsewhere.